Bank of America Securities Lifts PT on PTC Therapeutics (PTCT) to $87 From $76

Core Insights - PTC Therapeutics, Inc. is highlighted as a profitable biotech stock with a maintained Buy rating and an increased price target of $87 from $76 by Bank of America Securities analyst Tazeen Ahmad [1][2] Group 1: Company Performance - The initial demand for Sephience, PTC Therapeutics' newly approved treatment, is strong, with geneticists and neurologists already prescribing it and expecting an increase in prescriptions [2][3] - Early uptake of Sephience is particularly significant among patients who have not responded well to existing treatments like Kuvan [3] Group 2: Market Trends - There are promising early trends in payor coverage, with a high percentage of initial prescriptions being covered, indicating positive market reception [3]